Title

Association of *HLA-class II* alleles with risk of relapse in myeloperoxidase-antineutrophil cytoplasmic antibody positive vasculitis in the Japanese population.

Authors

Aya Kawasaki[1,2*], Ken-ei Sada[3,4], Premita Ari Kusumawati[1,2], Fumio Hirano[5,6], Shigeto Kobayashi[7], Kenji Nagasaka[8], Takahiko Sugihara[5,6] Nobuyuki Ono[9], Takashi Fujimoto[10], Makio Kusaoi[11], Naoto Tamura[11], Yasuyoshi Kusanagi[12], Kenji Itoh[12], Takayuki Sumida[13], Kunihiro Yamagata[14], Hiroshi Hashimoto[15], Hirofumi Makino[16], Yoshihiro Arimura[17,18], Masayoshi Harigai[19], Naoyuki Tsuchiya[1,2*].

Affiliations

[1]Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

[2]Master's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

[3]Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

[4]Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.

[5]Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

[6]Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

[7]Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama, Japan.

[8]Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan.

[9]Department of Rheumatology, Saga University, Saga, Japan

[10]Department of General Medicine, Nara Medical University, Kashihara, Japan.

[11]Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan.

[12]Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.

[13]Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

[14]Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

[15]Juntendo University School of Medicine, Tokyo, Japan.

[16]Okayama University, Okayama, Japan.

[17]Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Mitaka, Japan.

[18]Department of Internal Medicine, Kichijoji Asahi Hospital, Musashino, Japan.

[19]Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

Corresponding authors:

Aya Kawasaki, a-kawasaki@md.tsukuba.ac.jp

Naoyuki Tsuchiya, tsuchiya.nyk@gmail.com

Abstract

Background.

Disease relapse remains a major problem in the management of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In the European populations, *HLA-DPB1*04:01* is associated with both susceptibility and risk of relapse of proteinase 3 (PR3)-ANCA positive ANCA-associated vasculitis (AAV). In the Japanese population, we previously reported association of *HLA-DRB1*09:01* and *DQB1*03:03* with susceptibility to, and *DRB1*13:02* with protection from, myeloperoxidase-ANCA positive AAV (MPO-AAV). Subsequently, association of *DQA1*03:02*, which is in strong linkage disequilibrium with *DRB1*09:01* and *DQB1*03:03*, with susceptibility to MPO-AAV was reported in the Chinese population. However, association of these alleles with risk of relapse has not been reported. Here we examined whether *HLA-class II* is associated with risk of relapse in MPO-AAV.

Methods.

Firstly, association of *HLA-DQA1*03:02* with susceptibility to MPO-AAV and MPA, and its relationship with previously reported *DRB1*9:01* and *DQB1*03:03* was examined in 440 Japanese patients and 779 healthy controls. Next, association with risk of relapse was analyzed in 199 MPO-ANCA positive, PR3-ANCA negative patients enrolled in previously reported cohort studies of remission induction therapy. Uncorrected P values (P_{uncorr}) were corrected for multiple comparisons in each analysis using false discovery rate (FDR) method.

Results.

Association of *DQA1*03:02* with susceptibility to MPO-AAV and MPA was confirmed in the Japanese population (MPO-AAV: $P_{uncorr}=5.8x10^{-7}$, odds ratio [OR] 1.74, 95% confidence interval [CI] 1.40-2.16, MPA: $P_{uncorr}=1.1x10^{-5}$, OR 1.71, 95%CI 1.34-2.17). *DQA1*03:02* was in strong linkage disequilibrium with *DRB1*09:01* and *DQB1*03:03,* and the causal allele could not be determined using conditional logistic regression analysis. Relapse-free survival was shorter with nominal significance in carriers of

*DRB1*09:01* (P_{uncorr}=0.049, Q=0.42, hazard ratio [HR]:1.87), *DQA1*03:02* (P_{uncorr}=0.020, Q=0.22, HR:2.11) or *DQB1*03:03* (P_{uncorr}=0.043, Q=0.48, HR:1.91) when compared with non-carriers in log-rank test. On the other hand, carriers of serine at position 13 of HLA-DRβ1 (HLA-DRβ1_13S), including carriers of *DRB1*13:02,* showed longer relapse-free survival with nominal significance (P_{uncorr}=0.010, Q=0.42, HR:0.31). When the presence/absence of *DQA1*03:02* and HLA-DRβ1_13S are combined, significant difference was detected between the groups with highest and lowest risk for relapse (P_{uncorr}=0.0055, Q=0.033, HR:4.02).

Conclusion.

HLA-class II is associated not only with susceptibility to MPO-AAV but also with risk of relapse in the Japanese population.

Key Words:

ANCA-associated vasculitis, microscopic polyangiitis, MPO-ANCA, relapse, HLA-class II, genetics, polymorphism.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of necrotizing small vessel vasculitides characterized by production of ANCA, mainly directed against proteinase 3 (PR3) or myeloperoxidase (MPO). AAV is classified into microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) according to the European Medicines Agency (EMA) algorithm (1). In AAV, epidemiologic differences between European and Asian populations are well-known. In European populations, GPA and PR3-ANCA positive AAV (PR3-AAV) are predominant, while MPA and MPO-ANCA positive AAV (MPO-AAV) account for the majority of AAV in Japan (2). Such ethnic differences in epidemiology imply that genetic background may play a role in the development of AAV.

Although most AAV patients achieve remission by immunosuppressive therapy (3), a substantial proportion of them suffer from relapse. In the European populations, relapse occurs in approximately half of the GPA patients within 5 years after achieving complete remission (4). Among AAV patients, the risk of relapse has been shown to be higher in GPA and PR3-AAV compared with MPA and MPO-AAV (5). In Japanese observational studies to find risk factors for relapse of AAV, dosage and tapering speed of prednisolone were found to be associated with relapse (6, 7).

With respect to the susceptibility to MPA and GPA, three genome-wide association studies (GWAS) in European populations have been reported thus far (8-10). In GPA and PR3-AAV, the most striking association was identified in the *HLA-DP* region, which was consistent with previously reported association of GPA with *HLA-DPB1*04:01* in the German population (11). Additionally, *PRTN3* and *SERPINA1* genes, encoding PR3 and α1-antitrypsin, respectively, were identified as susceptibility genes (8,10). With respect to MPA and MPO-AAV, *HLA-DQ* region was found to be associated with

susceptibility in the GWAS (8,10). In agreement with this, *HLA-DRB1*09:01-DQB1*03:03* haplotype has been found to be associated with susceptibility to MPA and MPO-AAV in the Japanese population (12-15). In addition, *DQA1*03:02-DQB1*03:03* haplotype was recently reported to be associated with MPO-AAV in the Chinese population (16). *HLA-DRB1*09:01-DQA1*03:02-DQB1*03:03* haplotype is common in East Asian general populations, but rare in the European populations. Additionally, *DRB1*13:02* has been identified to be associated with protection from MPA and MPO-AAV in the Japanese population (14).

Although several genes have been associated with susceptibility to AAV, genes associated with relapse have not been well-characterized. In the European populations, *HLA-DPB1*04:01*, the susceptibility allele for GPA, has also been shown to be associated with higher risk of relapse in AAV (17) or in PR3-AAV (18). However, such studies have not been reported from East Asian populations, where MPA and MPO-AAV account for the majority of AAV.

In this study, we focused on MPO-AAV in the Japanese population, and examined whether *HLA-DRB1*, *DQA1*, *DQB1* and *DPB1* alleles are also associated with relapse in MPO-AAV, based on the clinical data in the Japanese nationwide cohort studies on remission induction therapy in AAV, “Remission Induction Therapy in Japanese Patients with ANCA-associated Vasculitides” (RemIT-JAV), registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000001648) (19) and “Remission Induction Therapy in Japanese Patients with ANCA-associated Vasculitides and Rapidly Progressive Glomerulonephritis” (RemIT-JAV-RPGN) (UMIN000005136) (20) carried out under the initiatives of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

Materials and Methods

Patients and controls

We first examined whether *HLA-DQA1*03:02*, recently reported in the Chinese population (16), is also associated with susceptibility to MPO-AAV and MPA in the Japanese population, and its relationship with *DRB1*09:01* and *DQB1*03:03* (12-15), in 440 patients with AAV (male: 168, female: 272) and 779 controls (male: 306, female: 473) The breakdown is shown in Table 1. Among these subjects, 362 MPO-AAV patients, 273 MPA patients and 514 controls were included in *HLA-DRB1* and *DPB1* analyses in our previous study (14).

Genomic DNA samples were recruited from the institutes participating in Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and Research Committee of Progressive Renal Disease, both organized by the Ministry of Health, Labour, and Welfare of Japan, and research groups organized by Tokyo Medical and Dental University and University of Tsukuba. Among the controls samples, 264 were obtained from the Health Science Research Resources Bank (Osaka, Japan).

Among the patients with MPO-AAV, 88 patients who enrolled in RemIT-JAV (19) and 176 in RemIT-JAV-RPGN (20) were analyzed for relapse-free survival. The characteristics of these cohorts were previously described (19,20). Briefly, the period of enrollment was from April 2009 to December 2010 (RemIT-JAV) and from April 2011 to March 2014 (RemIT-JAV-RPGN). The enrollment criteria were 1) diagnosis of AAV by the site investigators, 2) fulfilling the criteria for primary systemic vasculitis as proposed by the EMA algorithm, and 3) starting immunosuppressive treatment based on the discretion of the site investigators. Among the patients, 214 were MPO-ANCA single positive. To examine the rate of relapse after remission, 199 MPO-ANCA single

positive AAV patients who achieved remission during the observation period were analyzed in this study. The observation period was 730 days from the start of treatment. Eight out of 199 patients died during the observation period. Remission was defined based on the Birmingham vasculitis activity score (BVAS) 2003 (21) of zero on two consecutive occasions at least one month apart (22). Relapse was defined as the recurrence or new onset of clinical signs and symptoms attributable to active vasculitis (6, 23).

Detailed information on the subjects are available in Supplementary Data 1.

Genotyping

In all patients and controls, *HLA-DRB1* alleles were determined at the four-digit level using WAKFlow HLA typing kit (Wakunaga Pharmaceutical Co., Ltd., Osaka, Japan) based on polymerase chain reaction-sequence-specific oligonucleotide probes (PCR-SSOP). In 199 MPO-AAV patients, *HLA-DQA1*, *DQB1* and *DPB1* alleles were also genotyped using this system.

rs11545686C was used as the proxy for *HLA-DQA1*03:02*. Genotyping of rs11545686 was conducted by Sanger sequencing using 3130xl Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). For amplification of *HLA-DQA1* region surrounding rs11545686, forward (5'-TTTGGTTTGGGTGTCTTCAGATT-3') and reverse (5'-AAAGTTGTTCAGGGAAATTTGAGAATG-3') primers (Primer ID: Hs00412887_CE, Thermo Fisher Scientific) were used and cycle sequencing reaction was conducted using the forward primer and the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific).

Statistical analysis

Comparison of characteristics between the MPO-AAV patients with and without

relapse was performed using Fisher's exact test in two-by-two tables, except for age which was compared by Mann–Whitney U test.

Relapse-free survival curves were generated using the Kaplan-Meier method and were compared among the patients who were classified into GPA, MPA, EGPA and unclassifiable (UC) based on the EMA classification, among the patients treated with GC alone, GC plus immunosuppressants and immunosuppressants alone, and also between the patients with and without each *HLA class II* allele (*HLA-DRB1*, *DQA1*, *DQB1* and *DPB1*), and each amino acid encoded by these *HLA* alleles, by log-rank test. Unadjusted hazard ratios [HRs] and adjusted HRs for the EMA classification, treatment (GC alone, GC plus immunosuppressants or immunosuppressants alone), age and sex were calculated by Cox proportional hazard model.

Association of *HLA-DQA1*03:02* and *DRB1*09:01* with susceptibility to MPO-AAV and MPA was tested by logistic regression analysis under the additive model.

Statistical analyses were performed using R software version 3.5.2. Correction for multiple testing in the analyses of risk of relapse in each *HLA* locus and amino acid position was performed by controlling false discovery rate (FDR). $Q<0.1$ was considered significant. The numbers of comparisons were 17 (*DRB1* allele), 11 (*DQA1* allele), 11(*DQB1* allele), 8 (*DPB1* allele), 79 (DRβ1 amino acids), 47 (DQα1 amino acids), 71 (DQβ1 amino acids) and 26 (DPβ1 amino acids). The log-rank test for the pairwise comparison between combination of presence/absence of *DQA1*03:02* and DRβ1_13S was corrected for six comparisons, namely, combination of 2 out of 4 ($_4C_2=6$).

Ethics

This study was reviewed and approved by the Faculty of Medicine Ethics Committee,

University of Tsukuba (approval ID: 122, 123, 180, 227, 268).

In addition, this study was also approved by Ethics Committees of the following institutes which participated in collaboration and/or recruitment of the subjects: Aichi Medical University, Asahikawa Medical University, Ehime University, Fukuoka University, Hamamatsu University, Hokkaido University, Iwate Prefectural Central Hospital, Juntendo University, Kagawa University. Kanazawa University, Kitano Hospital, Kyorin University, Kyoto University, Kyushu University, Nagasaki University, Nagoya City University, Nagoya University, Nara Medical University, National Defense Medical College, Okayama University , Okayama Saiseikai General Hospital, Saga University, Saitama Medical Center Hospital, Shimane University, The University of Miyazaki, The University of Tokyo, Toho University, Tokyo Medical and Dental University, Tokyo Medical University Hachioji Medical Center, Tokyo Metropolitan Geriatric Hospital, and Institute of Gerontology, and Tokyo Women's Medical University.

This study was conducted in accordance with the principles of the Declaration of Helsinki and Ethical Guidelines for Human Genome/Gene Analysis Research implemented by Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry, of Japan.

This study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.

Results

Association of *HLA-DRB1*09:01-DQA1*03:02-DQB1*03:03* haplotype with susceptibility to MPO-AAV and MPA in the Japanese population

We previously reported that *DRB1*09:01* and *DQB1*03:03* are associated with susceptibility to, and *DRB1*13:02* with protection from, MPO-AAV and MPA in the Japanese population (12-15). Recently, *HLA-DQA1*03:02*, which is in strong linkage disequilibrium with *DRB1*09:01* and *DQB1*03:03*, has been reported to be associated with MPO-AAV in a Chinese population (16). Because association of *DQA1*03:02* with MPO-AAV as well as its relationship with *DRB1*09:01-DQB1*03:03* haplotype has not been previously analyzed in a Japanese population, we firstly addressed this issue.

In order to genotype *HLA-DQA1*03:02*, we used rs11545686 as a tag single nucleotide variant (tagSNV). rs11545686 codes for p.Met18Thr substitution within the signal peptide of the HLA-DQ alpha chain. rs11545686C allele is carried by *DQA1*03:02*, **03:07*, **03:13* and **03:18* based on the IPD-IMGT/HLA Database (Release 3.47.0, https://www.ebi.ac.uk/ipd/imgt/hla/). Except for *DQA1*03:02*, these alleles are extremely rare in the Japanese population. In fact, rs12722040, previously reported to tag *DQA1*03:02* (24), is identical to rs11545686. We confirmed that the *DQA1*03:02* genotyping system based on rs11545686 was concordant with the results of high-resolution allele typing using PCR-SSOP in 199 samples, except for one whose *DQA1* genotype could not be determined using PCR-SSOP.

Using this genotyping system, we examined association of *DQA1*03:02* with MPO-AAV and MPA. *DQA1*03:02* was significantly associated with susceptibility to MPO-AAV ($P_{unconditional}=5.8\times10^{-7}$) and MPA ($P_{unconditional}=1.1\times10^{-5}$) (Table 2), which confirmed the recent report on the Chinese population (16).

Strong linkage disequilibrium was observed among *DRB1*09:01*, *DQA1*03:02* and *DQB1*03:03* (r^2: 0.92-0.97). When the association was conditioned on each other, none of the association remained significant (Table 2). Therefore, we could not determine the single causative allele among *DRB1*09:01*, *DQA1*03:02* and *DQB1*03:03*.

Association of *HLA class II* alleles with relapse-free survival in MPO-AAV

Figure 1 shows the flow chart of the MPO-AAV patients enrolled in the relapse-free survival analysis. Among the 264 AAV patients who enrolled in the cohort studies RemIT-JAV (19) and RemIT-JAV-RPGN (20), more than 80% of the patients were MPO-ANCA positive and PR3-ANCA negative (hereafter referred to as “MPO-ANCA single positive”). Because the frequency of relapse was reported to be higher in AAV patients with PR3-ANCA when compared with those without (5), this study focused on 199 MPO-ANCA single positive patients who achieved remission during the observation period. The characteristics of the patients are shown in Table 3. During the first three months after treatment initiation, 84 (42.2%) received glucocorticoid (GC) alone, 112 (56.3%) were treated with GC plus immunosuppressants, and 3 with immunosuppressants alone (1.5%). In most of the patients, the immunosuppressant used was cyclophosphamide.

The mean observation period from the start of treatment was 676.7 (SD: 147.0) days. Among the 199 MPO-ANCA single positive AAV patients, relapse occurred in 39 patients (19.6%). The mean time to relapse after remission was 228.1 (SD: 173.5) days. No significant difference in sex ratio, age, clinical classification based on the EMA algorithm, the treatment received, and the observation period was observed between the patients with and without relapse (Table 3).

We next tested whether the EMA classification and the treatment modality are associated with risk of relapse using Kaplan-Meier method on the relapse-free survival. GPA patients have previously been shown to be associated with high occurrence of relapse (5). Significant difference in relapse-free survival was not observed among MPO-ANCA single positive AAV patients classified by the EMA algorithm (log-rank test uncorrected P [P_{uncorr}]=0.097) (Figure 2A) nor by the treatment modality (log-rank test P_{uncorr}=0.78)(Figure 2B).

The carrier frequency of each *HLA-DRB1*, *DQA1*, *DQB1* and *DPB1* allele in the MPO-AAV patients with and without relapse is shown in Supplementary Tables S1-S4. Carrier frequencies of *DRB1*09:01* (P_{uncorr}=0.049, Q=0.47, odds ratio [OR]: 2.05, 95% confidence interval [CI]: 1.01-4.15), *DQA1*03:02* (P_{uncorr}=0.020, Q=0.22, OR: 2.38, 95%CI: 1.16-4.87) and *DQB1*03:03* (P_{uncorr}=0.048, Q=0.53, OR: 2.10, 95%CI: 1.03-4.28) were nominally increased in the patients with relapse (Table 4). With respect to *DPB1* alleles, no trend toward association was observed among MPO-ANCA single positive AAV patients.

We next performed Kaplan-Meier method on the relapse-free survival between the carriers and non-carriers of each *HLA* allele (Supplementary Tables S1-S4). Nominal association was observed in *DQA1*03:02* (P_{uncorr}=0.020, Q=0.22), as well as *DRB1*09:01* (P_{uncorr}=0.049, Q=0.42) and *DQB1*03:03* (P_{uncorr}=0.043, Q=0.48) which are in linkage disequilibrium with *DQA1*03:02*. In addition, *DRB1*08:02* (P_{uncorr}=0.040, Q=0.42) was also found to be nominally associated with relapse.

Relapse-free survival curves and relapse-free survival rates at the end of the observation period in the nominally associated *HLA* alleles are shown in Figure 3A-3D and Table 5. The hazard ratios [HRs] for relapse were 2.11 (95% CI: 1.11-4.02) in *DQA1*03:02*, 1.87 (0.99-3.52) in *DRB1*09:01*, 1.91 (1.01-3.61) in *DQB1*03:03* and

2.30 (1.01-5.20) in *DRB1*08:02*. No violation of the proportional hazards assumption was observed in these alleles (P>0.05).

When HRs for the associated *HLA* alleles were conditioned on the EMA classification (MPA, GPA or UC), treatment modality during the initial three months (GC alone, immunosuppressants alone and GC plus immunosuppressants), age and sex using a multivariate Cox proportional hazards model, the associations of *DRB1*09:01*, *DQA1*03:02* and *DQB1*03:03* were not affected, while the association of *DRB1*08:02* was attenuated after conditioning (Table 5). In this analysis, EGPA was not included in the variables of EMA classification, because none of the patients with EGPA experienced relapse.

We next examined whether specific amino acids in HLA molecules are associated with relapse. The results of log-rank test for each amino acid are shown in Supplementary Data 2. The strongest trend for association was observed in serine residue at position 13 of HLA-DRβ1 (HLA-DRβ1_13S: log-rank P_{uncorr}=0.010, Q=0.42). Relapse-free survival was longer in the patients carrying HLA-DRβ1_13S (HR: 0.31, 95% CI: 0.12-0.80) (Figure 3E and Table 5).

When the associations of the *HLA* alleles nominally associated with the risk of relapse and HLA-DRβ1_13S were conditioned on each other, a tendency towards association remained in DRβ1_13S ($P_{conditional}$: 0.057 [conditional on *DQA1*03:02*] and 0.040 [conditional on *DQB1*03:03*]) (Table 6).

Finally, the patients were divided into four groups according to the carriage of *DQA1*03:02* (as a representative of *DRB1*09:01-DQA1*03:02-DQB1*03:03* relapse-risk haplotype) and DRβ1_13S (relapse-protective), and relapse-free survival was compared. As shown in Figure 3F, significant difference in time to relapse was

detected among the four groups (log-rank P=0.027). In the pairwise comparisons, significant difference was observed between the patients with highest risk combination (*DQA1*03:02* positive and DRβ1_13S negative) and with lowest risk for relapse combination (*DQA1*03:02* negative and DRβ1_13S positive), even after correction for multiple testing (HR: 4.02, 95% CI: 1.39-11.6, P_{uncorr}=0.0055, Q=0.033).

Discussion

In this study, we examined whether *HLA class II* alleles and HLA amino acids are associated with relapse in MPO-AAV, using the data from two Japanese nationwide cohort studies on remission induction therapy, RemIT-JAV (19) and RemIT-JAV-RPGN (20). We detected that MPO-ANCA single positive AAV patients carrying *HLA-DRB1*09:01*, *DQA1*03:02* or *DQB1*03:03* had nominally higher risk of relapse as compared with those without these alleles, while AAV patients carrying serine residue at position 13 of HLA-DRβ1 had a trend toward lower risk of relapse. By combining these two, significant differences were observed in the relapse-free survival among the subgroups of the patients. To our knowledge, this is the first study which demonstrated association of gene and amino acid variations with AAV relapse in the East Asian populations.

We previously identified the association of *HLA-DRB1*09:01* and *DQB1*03:03* with susceptibility to MPA/MPO-AAV in the Japanese population (12-15). In the present study, we confirmed the association of *DQA1*03:02* with susceptibility to MPO-AAV, recently reported in the Chinese population, in the Japanese population (16). Due to tight linkage disequilibrium among these three *HLA class II* alleles, we could not determine which of the three alleles plays a causative role.

A previous report showed that *HLA-DPB1*04:01*, the susceptibility allele to GPA, was also associated with an increased risk of relapse of AAV in the Dutch and German populations (17). In this study, GPA and PR3-AAV were predominant among the patients. On the other hand, such association was not observed in a Danish population (25). Although the reason for such discrepancy is unclear, difference in *DPB1*04:01* carrier frequency among the patients between these studies (77% (17) and 94% (25), respectively) might play a role. A recent study from the United States also reported association of *HLA-DPB1*04:01* with relapse in PR3-AAV, but not in MPO-AAV (18).

With respect to MPO-AAV, a small-scale study on MPO-AAV in a European population did not detect significant association between relapse and HLA-A, -B and -DR antigens (26). In our study, *HLA-DRB1*09:01*, *DQA1*03:02* and *DQB1*03:03*, the susceptibility alleles to MPO-AAV in East Asian populations (12-16) showed a trend toward higher risk of relapse of MPO-AAV in the Japanese population, possibly suggesting that the susceptibility alleles to AAV may also be associated with relapse in each ethnic group.

Unlike in one of the European studies (17), this study did not detect association of *DPB1*04:01* with risk of relapse of AAV. This is probably because this study focused on MPO-ANCA positive AAV, whereas in the European study, 51.7% of the subjects were positive for PR3-ANCA (17). In our data on MPO-AAV, no significant association was detected between *DPB1*04:01* and relapse (Supplementary Table S4), which is concordant with the report from the United States (18). This difference may not be explained merely by the low carrier frequency of *DPB1*04:01* in the Japanese population, because actually *DPB1*04:01* showed a slight tendency toward decrease in patients with relapse (P=0.70, OR: 0.39). In the Japanese population, the protective allele for MPO-AAV susceptibility, *DRB1*13:02*, is in linkage disequilibrium with *DPB1*04:01* (r^2=0.44), and the allele frequency of *DPB1*04:01* is also decreased in MPO-AAV (P=2.1x10^{-4}, OR: 0.40) due to linkage disequilibrium with *DRB1*13:02* (14). Thus, to evaluate the effect of *DPB1*04:01* in the Japanese population, PR3-ANCA positive AAV patients of sufficient sample size need to be investigated in the future.

On the other hand, alleles carrying HLA-DRβ1_13S were found to show a trend toward protection from relapse. HLA-DRβ1_13S is encoded by DR3, DR11, DR13 and DR14. HRs (95% CI) in *DRB1*11:01*, **13:02*, **14:05* and **14:54* were 0.49 (0.07-3.55), 0.31 (0.04-2.24), 0.77 (0.11-5.59) and 0.85 (0.26-2.76), respectively. All these alleles showed a tendency toward protection from relapse, although the differences did not

reach statistical significance. As mentioned above, we previously reported that *DRB1*13:02*, encoding HLA-DRβ1_13S, was protective from development of MPO-AAV (14). HLA-DRB1 position 13 amino acid has been associated with multiple immune system disorders, and was recently shown to be most strongly associated with individual differences in T cell receptor complementarity determining region 3 (CDR3) repertoire (27).

When the combined effect of *DQA1*03:02* and DRβ1_13S was examined, time to relapse was significantly shorter in the highest risk combination (*DQA1*03:02* positive and DRβ1_13S negative) when compared with the lowest risk combination (*DQA1*03:02* negative and DRβ1_13S positive), even after correction for multiple testing (Q=0.033). The HR of 4.02 was higher than the that of *HLA-DPB1*04:01* in the Dutch and the American studies (17,18).

In view of our present results, it could be hypothesized that the susceptibility alleles other than *HLA* may also be associated with risk of relapse in MPO-AAV. To date, no gene other than *HLA* has been established as a susceptibility gene to MPO-AAV in the Asian populations. In the European GWAS, *PTPN22* rs2476601 was reported to be associated with MPA/MPO-AAV as well as with GPA/PR3-AAV (10), but the risk allele of *PTPN22* is almost absent in the Asian populations. Recently, association of a *BACH2* variant has been identified by target sequencing (28). According to Genome Aggregation Database (gnomAD) (https://gnomad.broadinstitute.org/) (29), the risk allele of *BACH2* is also not detected in the East Asian populations. In the European population, it was reported that -463 A allele (rs2333227) in the *MPO* gene, associated with lower expression of MPO, was also associated with risk of relapse in MPO-AAV patients (30) which needs to be replicated by independent studies.

There are several limitations in this study. AAV is a rare disease, with annual incidence

of 22.6/million in Japan (2). Because of the limited sample size and lack of independent replication cohort, it should be emphasized that this study is of an exploratory nature. In addition, because this study is based on the observational cohort studies conducted between 2009 and 2016 (19,20), potential effects of currently available treatments such as rituximab and avacopan could not be addressed. In this study, relapse was defined as the recurrence or new onset of clinical signs and symptoms attributable to active vasculitis, similarly to the previous studies on the Japanese population (6,23). Although some of the previous studies employed more strict definition including a requirement for treatment escalation (17), we did not use this definition, because we thought that whether treatment is reinforced or not partly depends on each physician's decision, and might possibly cause a bias. Finally, the classification of AAV is based on EMA algorithm (1), and compatibility of our findings with 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria (31-33) needs to be validated. These limitations should be addressed in future independent studies.

Conclusion

In the present study, we demonstrated that *DRB1*09:01*, *DQA1*03:02* and *DQB1*03:03*, the susceptibility alleles to MPO-AAV, are also nominally associated with the risk of relapse in MPO-AAV in the Japanese population. In addition, we found that the carriers of HLA-DRβ1 allele with serine residue at position 13 are nominally associated with lower risk of relapse. By combining these two, statistically significant difference in the time to relapse was detected. These findings may potentially be relevant in detecting high risk individuals for relapse of AAV after remission, and accordingly adjusting treatment.

Contribution to the Field statement

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a group of rare systemic vasculitis, is classified into myeloperoxidase (MPO)-ANCA positive (MPO-AAV) and proteinase 3 (PR3)-ANCA positive (PR3-AAV) subsets. PR3-AAV accounts for the majority of AAV in the European populations, while MPO-AAV is dominant in the East Asian populations. Different types of human leukocyte antigens (HLA), which play a substantial role in individual's differences in immune responses, are associated with risk of PR3-AAV and MPO-AAV development.

Disease relapse is a major problem in the management of AAV, and biomarkers associated with the risk of relapse constitute unmet needs. HLA type associated with the risk of developing PR3-AAV has also been shown to be associated the risk of relapse in the European populations, but no study has been reported in MPO-AAV prevalent in East Asian populations.

Here we reported that the HLA types associated with higher and lower risk for the development of MPO-AAV also showed trend for higher and lower risk for relapse, respectively. When the risk and protective HLA types are combined, the difference reached statistical significance.

These findings may provide a clue for biomarkers which predict the risk of relapse of MPO-AAV, and eventually contribute to establishment of precision medicine. (199 words)

Data availability statement

The datasets supporting the conclusions of this article are included within the article, Supplementary Table S1-S4, Supplementary Data 1 and 2 files. Further inquiries can be directed to the corresponding authors.

Conflict of Interest

Dr. Kawasaki has received research grants from Ichiro Kanehara Foundation, Takeda Science Foundation, and Japan College of Rheumatology, and honoraria for lectures

from Chugai Pharmaceutical Co. Ltd.

Dr. Sada has received a research grant from Pfizer Inc., and honoraria for lectures from Glaxo SmithKline K.K.

Dr. Hirano has received honoraria for lectures from Janssen Pharmaceuticals, Ono Pharmaceuticals, and Mitsubishi Tanabe Pharma.

Dr, Kobayashi has received honoraria for the lectures from Novartis Pharma K.K, Eli Lilly Japan K.K., Chugai Pharma, Asahi Kasei Pharma, Gilead Sciences and Janssen Pharma K.K.

Dr. Nagasaka has received speaking fee from Chugai Pharmaceutical Co. Ltd.

Dr. Sugihara has received grants from AsahiKASEI Co., Ltd., Daiichi Sankyo, Chugai Pharmaceutical Co. and Ono Pharmaceutical, consulting fees from AsahiKASEI Co., Ltd., and honoraria for the lectures from Abbvie Japan Co., Ltd. AsahiKASEI Co., Ltd. Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd.

Dr. Tamura has received grants from Astellas, Ayumi, Asahi Kasei Pharma, Asahi Kasei Medical, AbbVie, Eisai, Nippon Boehringer Ingelheim, Novartis Pharma, Bayer Yakuhin, Tanabe Mitsubishi, Taisho, and Chugai. Dr. Tamura has received speaker fees and/or consulting fees from AbbVie, Eli Lilly Japan, Eisai, GlaxoSmithKline, Novartis, Bristol Myers Squibb, TanabeMitsubishi, Chugai and Janssen.

Dr. Itoh and Dr. Kusanagi have received grants from Asahi Kasei Pharma, Eizai, Teijin Pharma, and Chugai Pharmaceutical. Dr. Itoh has received honoraria for lectures from Asahi Kasei Pharma and Abbvie.

Dr. Makino has served on advisory boards for Boehringer Ingelheim and Travere Therapeutics.

Dr. Harigai has received grants from AbbVie Japan GK, Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Kissei

Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., and Teijin Pharma Ltd. Dr. Harigai has received consulting fee from Kissei Pharmaceutical Co., Ltd., honoraria for lectures from AbbVie Japan GK, Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Co., and Teijin Pharma Ltd., participation for Advisory Board for Kissei Pharmaceutical Co., Ltd.

Dr. Tsuchiya has received grants from Bristol-Myers Squibb K.K., the Naito Foundation, the Uehara Memorial Foundation, and collaborative research fund from H.U. Group Research Institute G.K.. Dr. Tsuchiya has received award grants from Japan College of Rheumatology and Japan Rheumatism Foundation, and honoraria for lectures from Teijin Ltd.

Other authors have no competing interest to disclose.

Author Contributions

Dr. Kawasaki and Dr. Tsuchiya designed the study, interpreted the data and wrote the manuscript. Dr. Sada, Dr. Yamagata, Dr. Hashimoto, Dr. Makino, Dr. Arimura and Dr. Harigai coordinated the cohorts. Dr. Kawasaki and Ms. Premita Ari performed genotyping and statistical analyses. Dr. Sada, Dr. Hirano, Dr. Kobayashi, Dr. Nagasaka, Dr. Sugihara, Dr. Ono, Dr. Fujimoto, Dr. Kusaoi, Dr. Tamura, Dr. Kusanagi, Dr. Itoh and Dr. Sumida recruited the participants and collected clinical data. All authors read and approved the final version of the manuscript.

Funding:

This work was supported by the grants from the Japan Agency for Medical Research and Development "The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence [grant number 17ek0109104h0003]", "The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline [grant number 17ek0109121h0003]", and "Multitiered

study to address clinical questions for management of intractable vasculitides [grant number 20ek0109360h003]", Ministry of Health, Labour and Welfare [grant number JP20FC1044], Japan Society for the Promotion of Science KAKENHI [grant number JP17K09967, JP21K08435], research grants from Bristol-Myers Squibb K.K., Ichiro Kanehara Foundation, Takeda Science Foundation, the Uehara Memorial Foundation and award grants from Japan College of Rheumatology and Japan Rheumatism Foundation. The funders had no role in the design, analysis, interpretation and paper writing of this study.

Acknowledgements

The authors are grateful to all the patients for participating in this study, and to the clinical staff associated with Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan for recruiting the patients and collecting clinical information.

References

1. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, *et al.* Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis* (2007) 66:222-7. doi:10.1136/ard.2006.054593
2. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, *et al.* Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. *Rheumatology* (2011) 50:1916-20. doi:10.1093/rheumatology/ker205
3. Novikov PI, Smitienko I, Moiseev SV. Duration of maintenance therapy for ANCA-associated vasculitis: more questions than answers. *Ann Rheum Dis* (2018) 77:e29.doi:10.1136/annrheumdis-2017-211972
4. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Pagnoux C, Coste J, Guillevin L, *et al.* Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. *Rheumatology* (2010) 49:2181-90.doi:10.1093/rheumatology/keq244
5. Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, *et al.* Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. *Ann Rheum Dis* (2018) 77:1151-7. doi:10.1136/annrheumdis-2017-212768
6. Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. *J Rheumatol* (2012) 39:545-51. doi:10.3899/jrheum.110705
7. Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, *et al.* Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis in Japan: A nationwide, prospective cohort study. *J Rheumatol* (2018) 45:521-8. doi:10.3899/jrheum.170508
8. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* (2012) 367:214-

23. doi:10.1056/NEJMoa1108735

9. Xie G, Roshandel D, Sherva R, Monach PA, Lu EY, Kung T, *et al.* Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. *Arthritis Rheum* (2013) 65:2457-68. doi:10.1002/art.38036
10. Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J, *et al.* Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. *Arthritis Rheumatol* (2017) 69:1054-66. doi:10.1002/art.40034
11. Heckmann M, Holle JU, Arning L, Knaup S, Hellmich B, Nothnagel M, *et al.* The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. *Ann Rheum Dis* (2008) 67:972-9. doi:10.1136/ard.2007.077693
12. Tsuchiya N, Kobayashi S, Kawasaki A, Kyogoku C, Arimura Y, Yoshida M, *et al.* Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. *J Rheumatol* (2003) 30:1534-40.
13. Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K. Association of HLA-*DRB1*0901-DQB1*0303* haplotype with microscopic polyangiitis in Japanese. *Genes Immun* (2006) 7:81-4. doi: 10.1038/sj.gene.6364262.
14. Kawasaki A, Hasebe N, Hidaka M, Hirano F, Sada KE, Kobayashi S, *et al.* Protective role of HLA-DRB1*13:02 against microscopic polyangiitis and MPO-ANCA-positive vasculitides in a Japanese population: a case-control study. *PLoS One* (2016) 11:e0154393. doi:10.1371/journal.pone.0154393
15. Kawasaki A, Tsuchiya N. Advances in the genomics of ANCA-associated vasculitis-a view from East Asia. *Genes Immun* (2021) 22:1-11. doi: 10.1038/s41435-021-00123-x
16. Wang HY, Cui Z, Pei ZY, Fang SB, Chen SF, Zhu L, *et al.* Risk HLA class II alleles

and amino acid residues in myeloperoxidase-ANCA-associated vasculitis. *Kidney Int* (2019) 96:1010-9. doi:10.1016/j.kint.2019.06.015

17. Hilhorst M, Arndt F, Kemna MJ, Wieczorek S, Donner Y, Wilde B, *et al.* HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study. *Arthritis Rheumatol* (2016) 68:1721-30. doi:10.1002/art.39620
18. Chen DP, McInnis EA, Wu EY, Stember KG, Hogan SL, Hu Y, *et al*. Immunological interaction of HLA-DPB1 and proteinase 3 in ANCA vasculitis is associated with clinical disease activity. *J Am Soc Nephrol* (2022) 33:1517-27. doi: 10.1681/ASN.2021081142
19. Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, *et al.* Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Arthritis Res Ther* (2014) 16:R101. doi:10.1186/ar4550
20. Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, *et al.* Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Mod Rheumatol* (2016) 26:730-7. doi:10.3109/14397595.2016.1140274
21. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, *et al.* Development of comprehensive disease assessment in systemic vasculitis. *Ann Rheum Dis* (2007) 66:283-92. doi:10.1136/ard.2005.051078
22. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, *et al.* EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. *Ann Rheum Dis* (2007) 66:605-17. doi:10.1136/ard.2006.062711
23. Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Dobashi H, *et al.* Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-

associated vasculitis: subgroup analysis of nationwide prospective cohort studies. *Arthritis Rheumatol* (2018) 70:1626-33. doi:10.1002/art.40538

24. Zhou F, Cao H, Zuo X, Zhang T, Zhang X, Liu X, *et al.* Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. *Nat Genet* (2016) 48:740-6. doi:10.1038/ng.3576
25. Gregersen JW, Erikstrup C, Ivarsen P, Glerup R, Krarup E, Keller KK, *et al.* PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. *Rheumatology* (2019) 58:1942-9. doi:10.1093/rheumatology/kez111
26. Stassen PM, Cohen-Tervaert JW, Lems SP, Hepkema BG, Kallenberg CGM, Stegeman CA, *et al.* HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. *Rheumatology* (2009) 48:622-5. doi:10.1093/rheumatology/kep057
27. Ishigaki K, Lagattuta KA, Luo Y, James EA, Buckner JH, Raychaudhuri S. HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors. Nat Genet (2022) 54:393-402. doi: 10.1038/s41588-022-01032-z
28. Dahlqvist J, Ekman D, Sennblad B, Kozyrev SV, Nordin J, Karlsson A, *et al.* Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. *Rheumatology* (2022) 61:3461-70. doi: 10.1093/rheumatology/keab912
29. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* (2020) 581:434-43. doi:10.1038/s41586-020-2308-7
30. Reynolds WF, Stegeman CA, Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. *Clin Immunol* (2002) 103:154-60. doi:10.1006/clim.2002.5206
31. Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, *et al.* 2022

American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. *Ann Rheum Dis* (2022) 81:309–14. doi: 10.1136/annrheumdis-2021-221794.

32. Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, *et al.* 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. *Ann Rheum Dis* (2022) 81:315–20. doi: 10.1136/annrheumdis-2021-221795.
33. Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, *et al*. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. *Ann Rheum Dis* (2022) 81:321–6. doi: 10.1136/annrheumdis-2021-221796.

Table 1. Characteristics of the patients and healthy controls examined for the association of *HLA-DRB1*09:01* and *DQA1*03:02* with susceptibility to MPO-AAV and MPA.

	MPO-AAV/MPA	Healthy controls
n	440	779
Sex (Male : Female)	168 : 272	306 : 473
EMA classification		
MPA	305	NA
GPA	64	NA
EGPA	36	NA
Unclassifiable	35	NA
ANCA specificity		
MPO-ANCA	428	NA
PR3-ANCA	18	NA

n, number; SD, standard deviation; MPO-AAV, MPO-ANCA positive ANCA-associated vasculitis; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; NA, not applicable. Note that MPO-ANCA negative GPA, EGPA and unclassifiable AAV are not included in this study. Detailed information is available in Supplementary Data 1.

Table 2. Association of *DQA1*03:02* with susceptibility to MPO-ANCA positive AAV and MPA

	n (allele frequency: %)			$P_{conditional}$ / OR (95%CI)* on:	
	case	healthy controls	$P_{unconditional}$ / OR (95%CI)	*DRB1*09:01*	*DQA1*03:02*
MPO-AAV	2n=856	2n=1558			
*DRB1*09:01*	190 (22.2)	222 (14.2)	6.9×10^{-7} / 1.75 (1.40-2.19)	NA	0.45 / 1.29 (0.67-2.53)
*DQA1*03:02*	202 (23.6)	240 (15.4)	5.8×10^{-7} / 1.74 (1.40-2.16)	0.33 / 1.37 (0.71-2.61)	NA
MPA	2n=610	2n=1558			
*DRB1*09:01*	137 (22.5)	222 (14.2)	4.2×10^{-6} / 1.77 (1.39-2.26)	NA	0.19 / 1.68 (0.79-3.83)
*DQA1*03:02*	143 (23.4)	240 (15.4)	1.1×10^{-5} / 1.71 (1.34-2.17)	0.89 / 1.05 (0.47-2.20)	NA

OR: odds ratio, CI: confidence interval, MPO-AAV: MPO-ANCA positive ANCA-associated vasculitis, MPA: microscopic polyangiitis, NA: not applicable.

*$P_{conditional}$, OR and 95% CI were conditional on *DRB1*09:01* or *DQA1*03:02* in conditional logistic regression analysis.

Table 3. Characteristics of the MPO-ANCA single positive AAV with and without relapse

	Relapse (+)	Relapse (-)	P
n (%)	39 (19.6)	160 (80.4)	
Sex (Male : Female)	15 : 24	63 : 97	1.0
Age (mean ± SD)	69.7 ± 10.1	69.9 ± 11.3	0.76
EMA classification: n (%)			
MPA	26 (66.7)	115 (71.9)	0.56
GPA	8 (20.5)	17 (10.6)	0.11
EGPA	0 (0)	12 (7.5)	0.13
Unclassifiable	5 (12.8)	16 (10.0)	0.57
Treatment*			
GC alone	15 (38.5)	69 (43.1)	referent
GC plus immunosuppressants	23 (59.0)	89 (55.6)	0.72
Immunosuppressants alone	1 (2.6)	2 (1.3)	0.46
Observation period (mean ± SD)			
From the start of treatment	673.3 ± 148.3	677.5 ± 147.2	0.87
After the achievement of remission	577.4 ± 151.5	575.2 ± 160.6	0.94

n: number, SD: standard deviation, GC: glucocorticoid.

P values were calculated using Fisher's exact test in the comparisons of sex, EMA classification and treatment. Mann–Whitney U test was used for age, and t-test for observation period.

*treatment during the first three months after initiation.

Detailed information is available in Supplementary Data 1.

Table 4. Association of *HLA class II* alleles with occurrence of relapse and risk of relapse

HLA	Carrier frequency					Relapse-free survival	
	Relapse (+: n=39) n (%)	Relapse (-: n=160) n (%)	P_{uncorr} [*1]	Q [*1]	OR (95%CI)	P_{uncorr} [*2]	Q [*2]
*DRB1*08:02*	7 (17.9)	11 (6.9)	0.055	0.47	2.96 (1.07-8.23)	0.040	0.42
*DRB1*09:01*	22 (56.4)	62 (38.8)	0.049	0.47	2.05 (1.01-4.15)	0.049	0.42
*DQA1*03:02*	24 (61.5)	64 (40.3) [*3]	0.020	0.22	2.38 (1.16-4.87)	0.020	0.22
*DQB1*03:03*	23 (59.0)	65 (40.6)	0.048	0.53	2.10 (1.03-4.28)	0.043	0.48

OR: odds ratio, CI: confidence interval.

[*1]Carrier frequency (%) of each *HLA* allele was compared between the patients with and without relapse by Fisher's exact test. Uncorrected P values (P_{uncorr}) and false discovery rate (FDR) Q values are shown.

[*2]Time to relapse after achievement of remission was compared between the patients carrying and not-carrying each *HLA* allele using log-rank test. P_{uncorr} values for the relapse-free survival rate calculated by Kaplan-Meier method and FDR Q values are shown.

[*3]One patient, whose *HLA-DQA1* genotype could not be determined, was excluded from the analysis of *HLA-DQA1*.

Table 5. Association of *HLA class II* alleles and DRβ1 position 13 serine with risk of relapse in multivariate Cox proportional hazards model

	relapse-free survival rate (95% CI)			$P_{conditional}$ / HR (95%CI)* on:		
	positive patients	negative patients	$P_{unconditional}$ / HR (95%CI)	MPA	GPA	Unclassifiable
HLA-allele						
*DRB1*08:02*	61.1 (42.3-88.3)	80.2 (74.1-86.8)	0.046 / 2.30 (1.01-5.20)	0.051 / 2.28 (1.00-5.19)	0.088 / 2.07 (0.90-4.77)	0.049 / 2.29 (1.00-5.23)
*DRB1*09:01*	70.6 (60.6-82.3)	84.1 (77.4-91.4)	0.053 / 1.87 (0.99-3.52)	0.046 / 1.93 (1.01-3.67)	0.040 / 1.96 (1.03-3.73)	0.045 / 1.94 (1.02-3.69)
*DQA1*03:02*	69.4 (59.5-81.0)	85.4 (78.7-92.5)	0.023 / 2.11 (1.11-4.02)	0.020 / 2.18 (1.13-4.19)	0.013 / 2.29 (1.19-4.41)	0.019 / 2.19 (1.14-4.23)
*DQB1*03:03*	70.6 (60.8-82.1)	84.5 (77.7-91.8)	0.047 / 1.91 (1.01-3.61)	0.041 / 1.96 (1.03-3.75)	0.034 / 2.02 (1.06-3.85)	0.039 / 1.98 (1.03-3.78)
HLA-amino acid						
DRβ1_13S	90.9 (83.5-98.9)	73.0 (65.3-81.5)	0.015 / 0.31 (0.12-0.80)	0.014 / 0.31 (0.12-0.79)	0.018 / 0.32 (0.12-0.82)	0.014 / 0.30 (0.12-0.78)

HR: hazard ratio, CI: confidence interval, MPA: microscopic polyangiitis, GPA: granulomatosis with polyangiitis.

*$P_{condiional}$, HR and 95% CI conditional on EMA classification (MPA, GPA or unclassifiable), treatment, age and sex in multivariate Cox proportional hazards model. EGPA was not included in variables of the EMA classification, because none of the patients with EGPA experienced relapse.

Table 6. Conditional survival analysis of *HLA* alleles and DRβ1 position 13 serine in multivariate Cox proportional hazards model

	$P_{unconditional}$ / HR (95%CI)	$P_{conditional}$ / HR (95%CI)* on:			
		*DRB1*09:01*	*DQA1*03:02*	*DQB1*03:03*	DRβ1_13S
HLA-allele					
*DRB1*09:01*	0.053 / 1.87 (0.99-3.52)	NA	0.63 / 0.70 (0.16-2.97)	0.85 / 1.18 (0.21-6.72)	NA
*DQA1*03:02*	0.023 / 2.11 (1.11-4.02)	0.15 / 2.95 (0.67-12.9)	NA	0.052 / 7.45 (0.98-56.7)	0.15 / 1.65 (0.84-3.23)
*DQB1*03:03*	0.047 / 1.91 (1.01-3.61)	0.58 / 1.63 (0.28-9.39)	0.21 / 0.27 (0.04-2.04)	NA	0.24 / 1.49 (0.77-2.89)
HLA -amino acid					
DRβ1_13S	0.015 / 0.31 (0.12-0.80)	NA	0.057 / 0.39 (0.15-1.03)	0.040 / 0.36 (0.14-0.96)	NA

HR: hazard ratio, CI: confidence interval, NA: not applicable.

*$P_{conditional}$, HR and 95% CI were conditioned on indicated HLA alleles or amino acid in multivariate Cox proportional hazards model.

Figure Legends

Figure 1. Flow chart of the MPO-AAV patients in the relapse-free survival analysis.

Among the patients who entered the cohort studies of remission induction therapy (RemIT-JAV and RemIT-JAV-RPGN), 199 MPO-ANCA positive and PR3-ANCA negative ("MPO-ANCA single positive") patients who achieved remission were studied in the relapse-free survival analysis.

Figure 2. Relapse-free survival in MPO-ANCA single positive AAV patients according to the EMA classification and treatment modality.

The longitudinal and horizontal axes represent the probability of relapse-free survival and days after achievement of remission, respectively. P value was calculated by log-rank test. (A) Relapse-free survival was compared among MPO-ANCA single positive, MPA (n=141), GPA (n=25), EGPA (n=12) and unclassifiable AAV (UC) (n=21). Note that PR3-ANCA positive patients are not included in any group. (B) Relapse-free survival was compared among MPO-ANCA single positive AAV patients treated with glucocorticoid (GC) alone (n=84), GC plus immunosuppressants (n=112) and immunosuppressants alone (n=3).

Figure 3. Association of *HLA* alleles and DRβ1 position 13 serine with relapse-free survival in MPO-ANCA single positive AAV patients by Kaplan-Meier method.

The longitudinal and horizontal axes represent the probability of relapse-free survival and days after achievement of remission, respectively. Uncorrected P values calculated by log-rank test are shown. Q values corrected for multiple comparisons for each locus are shown in the text, Table 4 and Table 5. Relapse-free survival was compared between MPO-ANCA single positive AAV patients carrying and not carrying

(A) *HLA-DRB1*09:01*, **(B)** *HLA-DRB1*08:02*, **(C)** *HLA-DQA1*03:02*, **(D)** *HLA-DQB1*03:03* and **(E)** HLA-DRβ1 position 13 serine (HLA-DRβ1_13S). **(F)** the patients were divided into four groups according to the carriage of *HLA-DQA1*03:02* and HLA-DRβ1_13S. Relapse-free survival was compared among *DQA1*03:02* (+) and DRβ1_13S (-) (n=79), *DQA1*03:02* (-) and DRβ1_13S (+) (n=49), *DQA1*03:02* (-) and DRβ1_13S (-) (n=61) and *DQA1*03:02* (+) and DRβ1_13S (+) (n=9) groups.


264 AAV patients: RemIT-JAV (n=88)
RemIT-JAV-RPGN (n=176)
negative for MPO-ANCA (n=41)
double positive for MPO and PR3-ANCA (n=8)
ANCA-specificity data not available (n=1)
214 MPO-ANCA single positive AAV patients
remission not achieved (n=13)
remission data not available (n=2)
199 MPO-ANCA single positive AAV patients who achieved remission
with relapse (n=39)
without relapse (n=160)

Figure 1


A
Relapse-free survival
1.0
0.8
0.6
0.4
0.2
0.0
log-rank P = 0.097
MPO-ANCA single positive MPA
MPO-ANCA single positive GPA
MPO-ANCA single positive EGPA
MPO-ANCA single positive UC
0
100
200
300
400
500
600
700
Days after achieving remission
B
Relapse-free survival
1.0
0.8
0.6
0.4
0.2
0.0
log-rank P = 0.78
GC alone
GC plus immunosuppressants
Immunosuppressants alone
0
100
200
300
400
500
600
700
Days after achieving remission

Figure 2


A
Relapse-free survival
log-rank P = 0.049
DRB1*09:01 (+)
DRB1*09:01 (-)
Days after achieving remission
B
Relapse-free survival
log-rank P = 0.040
DRB1*08:02 (+)
DRB1*08:02 (-)
Days after achieving remission
C
Relapse-free survival
log-rank P = 0.020
DQA1*03:02 (+)
DQA1*03:02 (-)
Days after achieving remission
D
Relapse-free survival
log-rank P = 0.043
DQB1*03:03 (+)
DQB1*03:03 (-)
Days after achieving remission
E
Relapse-free survival
log-rank P = 0.010
DRβ1_13S (+)
DRβ1_13S (-)
Days after achieving remission
F
Relapse-free survival
log-rank P = 0.027
DQA1*03:02 (+), DRβ1_13S (-)
DQA1*03:02 (-), DRβ1_13S (+)
DQA1*03:02 (-), DRβ1_13S (-)
DQA1*03:02 (+), DRβ1_13S (+)
Days after achieving remission

Figure 3